TELEREHAB2: Telerehabilitation in the Home After Stroke
TELEREHAB2 is a national phase III, randomized, assessor-blinded trial conducted through NIH StrokeNet. The study tests whether six weeks of intensive, home-based telerehabilitation for arm movement, added to usual care, improves arm function and reduces disability compared with usual care alone in adults 3-5 months after ischemic or hemorrhagic stroke. Participants assigned to telerehabilitation use a computer-based system through interactive games and exercises for 70 minutes per day, six days per week, with online support from a licensed physical or occupational therapist. This is an extremely innovative and novel way of delivering neurorehabilitation and stroke recovery therapy which is not dependent on any scheduled but rare outpatient clinic visits. Baystate Medical Center, led by site PI Gottfried Schlaug, MD, PhD, is actively recruiting eligible participants.
This research study is led by Gottfried Schlaug, MD, PhD
Contact: Abraham Madjidov, 208-571-0434, Abraham.Madjidov@baystatehealth.org
Participation Details:
Start Date: August 22, 2025
Estimated End Date: June 2030
Time Commitment: The main study period lasts about 8 months and includes 4 in-person visits, one brain MRI, and several brief phone calls. Participants assigned to telerehabilitation complete 36 therapy sessions at home over 6 weeks (70 minutes per day, 6 days per week), with half supervised online by a licensed therapist and half completed independently based on instructions by a therapist. Participants assigned to usual care may receive their usual and standard therapy and then novel at home therapy program after the 8-month visit.
IRB Number: 2330830
ClinicalTrials.gov ID: NCT06682429
Primary Sponsor: The study is funded by the National Institute of Neurological Disorders and Stroke (NINDS), and conducted through NIH StrokeNet with primary coordinating centers at University of California Los Angeles and Moss Rehabilitation Research Institute in Philadelphia.
Location:
Eligibility:
- Inclusion: Adults aged 18-80 with moderate to severe arm weakness who had a stroke 3-5 months ago.
- Exclusion: Significant cognitive or communication problems; severe arm spasticity or contracture; pregnancy; or an MRI contraindication.
Status: Active
Phase: Phase III randomized, controlled, assessor-blinded superiority trial
Back to Top